ESMO VIRTUAL PRECEPTORSHIP PROGRAMME
GASTRIC CANCER
Multidisciplinary management, standards of care and future perspectives
17-18 November 2021

CO-CHAIRS: Florian Lordick, Germany
Matthew C. H. Ng, Singapore

SPEAKERS: Hanneke van Laarhoven, Netherlands
Tony K. H. Lim, Singapore
Brigette Ma, Hong Kong
Joanne Y. Y. Ngeow, Singapore
Sun Young Rha, South Korea
Jimmy B. Y. So, Singapore
Wei Peng Yong, Singapore

LEARNING OBJECTIVES

- To learn the fundamental of epidemiology, aetiology, pathogenesis, molecular events, and ethnic patterns as contributing factors to heterogeneity in gastric cancer (GC)
- To understand the importance of pathology and molecular factors
- To learn about best clinical practice in the multidisciplinary management of gastric and gastro-esophageal junction (GEJ) in the adjuvant and metastatic settings
- To learn about current best practice for endoscopic and surgical resection of localized gastric cancer
- To be able to compare the benefits of neo-adjuvant, adjuvant approaches and the value of radiotherapy in the management of localized gastro-esophageal cancers
- To learn about the management of patients after progression, in special situations and side effects of treatments
- To learn about the advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with 6 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

AMGEN

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
All timings are to be considered GMT+8 (Singapore Local Time)

**Wednesday, 17 November 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00-15:05</td>
<td>Welcome and introduction</td>
<td>Florian Lordick, DE</td>
</tr>
<tr>
<td>15:05-17:25</td>
<td>SESSION 1 Epidemiology, pathology and multidisciplinary management of</td>
<td>Matthew C. H. Ng, SG</td>
</tr>
<tr>
<td></td>
<td>localized gastric cancer</td>
<td></td>
</tr>
<tr>
<td>15:05-15:25</td>
<td>Epidemiology, pathogenesis and molecular subtypes</td>
<td>Brigette Ma, HK</td>
</tr>
<tr>
<td>15:25-16:05</td>
<td>How pathology can guide treatment: HER2, MSI, PDL1 and EBV</td>
<td>Tony K. H. Lim, SG</td>
</tr>
<tr>
<td>16:05-16:45</td>
<td>Advances in surgery: endoscopic, minimally invasive, optimal nodal</td>
<td>Jimmy B. Y. So, SG</td>
</tr>
<tr>
<td></td>
<td>dissection and organ-sparing (spleen, omentum)</td>
<td></td>
</tr>
<tr>
<td>16:45-17:25</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>16:15-16:25</td>
<td>Break</td>
<td>Matthew C. H. Ng, SG</td>
</tr>
<tr>
<td>17:25-18:25</td>
<td>SESSION 2 Participants clinical case discussion</td>
<td>Florian Lordick, DE</td>
</tr>
<tr>
<td>17:25-18:25</td>
<td>Participants clinical case discussion (4x15') (localized)</td>
<td>Faculty</td>
</tr>
</tbody>
</table>

**Thursday, 18 November 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00-15:30</td>
<td>SESSION 3 Cancer genetics</td>
<td>Florian Lordick, DE</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>A practical approach to hereditary gastric cancers</td>
<td>Joanne Y. Y. Ngeow, SG</td>
</tr>
<tr>
<td>15:30-16:30</td>
<td>SESSION 4 Metastatic gastric cancer</td>
<td></td>
</tr>
<tr>
<td>15:30-16:30</td>
<td>Optimizing chemotherapy and molecularly targeted therapy</td>
<td>Wei Peng Yong, SG</td>
</tr>
<tr>
<td>15:30-16:30</td>
<td>Immunotherapy monotherapy or in combination and when best to give it</td>
<td>Sun Young Rha, KR</td>
</tr>
<tr>
<td>15:30-16:30</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>16:30-16:40</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>16:30-16:40</td>
<td>Approaches to treat oligometastatic disease</td>
<td>Hanneke van Laarhoven, NL</td>
</tr>
<tr>
<td>16:30-16:40</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Chair/Moderator</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>17:10-18:10</td>
<td>SESSION 5 Participants clinical case discussion</td>
<td>Matthew C. H. Ng, SG</td>
</tr>
<tr>
<td>18:10-18:15</td>
<td>Conclusion and farewell</td>
<td>Florian Lordick, DE</td>
</tr>
<tr>
<td>18:10-18:15</td>
<td></td>
<td>Matthew C. H. Ng, SG</td>
</tr>
</tbody>
</table>

Note: Each 15-minute slot for clinical case discussion includes 7’ case presentation and 8’ Q&A / panel discussion